日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Safety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial

三氟尿苷/替吡嘧啶联合或不联合贝伐珠单抗加XB2001(抗IL-1α抗体)的安全性和有效性:一项单中心1期试验

Marion Thibaudin ,Nicolas Roussot ,Chloé Burlot ,Antonin Schmitt ,Julie Vincent ,Zoé Tharin ,Leila Bengrine ,Hélène Bellio ,Aurélie Bertaut ,Léa Hampe ,Susy Daumoine ,Emilie Rederstorff ,Morgane Peroz ,Titouan Huppe ,Valentin Derangère ,David Rageot ,John Simard ,Caroline Truntzer ,Jean David Fumet ,Francois Ghiringhelli

FOLFIRINOX-3 plus bevacizumab (bFOLFIRINOX3) in chemo-refractory metastatic colorectal cancer: a multicenter phase II trial

FOLFIRINOX-3联合贝伐单抗(bFOLFIRINOX3)治疗化疗难治性转移性结直肠癌:一项多中心II期试验

Bellio, Hélène; Roussot, Nicolas; Bertaut, Aurélie; Hervieu, Alice; Zanetta, Sylvie; Tharin, Zoe; Vincent, Julie; Bengrine, Leila; Hennequin, Audrey; Guion, Jean-Florian; Boudrant, Axelle; Collot, Thomas; Ghiringhelli, Francois; Fumet, Jean-David

Case report: Immune response characterization of a pseudoprogression in a PD-L1-negative, TMB-low, KEAP1/STK11 co-mutated metastatic NSCLC

病例报告:PD-L1 阴性、TMB 低、KEAP1/STK11 共突变转移性 NSCLC 中假进展的免疫反应特征

Nicolas Roussot, Marion Thibaudin, Jean-David Fumet, Susy Daumoine, Léa Hampe, Cédric Rébé, Emeric Limagne, Aurélie Lagrange, Victor Herreros, Julie Lecuelle, Hugo Mananet, Alis Ilie, David Rageot, Romain Boidot, Vincent Goussot, Anthony Comte, Pierre Jacob, Françoise Beltjens, Anthony Bergeron, Cél

Improving olaparib exposure to optimize adverse effects management

提高奥拉帕尼暴露量以优化不良反应管理

Sterlé, Marylise; Puszkiel, Alicja; Burlot, Chloé; Pereira, Eva; Bellesoeur, Audrey; De Percin, Sixtine; Beinse, Guillaume; Fumet, Jean-David; Favier, Laure; Niogret, Julie; Blanchet, Benoit; Royer, Bernard; Bengrine-Lefevre, Leïla; Schmitt, Antonin

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial

RAS 突变转移性结直肠癌的一线治疗:durvalumab 和 tremelimumab 联合化疗:一项 1b/2 期试验

Marion Thibaudin, Jean-David Fumet, Benoist Chibaudel, Jaafar Bennouna, Christophe Borg, Jerome Martin-Babau, Romain Cohen, Marianne Fonck, Julien Taieb, Emeric Limagne, Julie Blanc, Elise Ballot, Léa Hampe, Marjorie Bon, Susy Daumoine, Morgane Peroz, Hugo Mananet, Valentin Derangère, Romain Boidot,

Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer

利用CD8和PD-L1标志物的空间定量分析进行免疫检查点评分的免疫评分可预测抗PD-1/PD-L1免疫疗法在非小细胞肺癌中的疗效。

Ghiringhelli, François; Bibeau, Frederic; Greillier, Laurent; Fumet, Jean-David; Ilie, Alis; Monville, Florence; Laugé, Caroline; Catteau, Aurélie; Boquet, Isabelle; Majdi, Amine; Morgand, Erwan; Oulkhouir, Youssef; Brandone, Nicolas; Adam, Julien; Sbarrato, Thomas; Kassambara, Alboukadel; Fieschi, Jacques; Garcia, Stéphane; Lepage, Anne Laure; Tomasini, Pascale; Galon, Jérôme

Corrigendum to "Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer": [ESMO Open 3 (2018) e000375]

对“评估度伐利尤单抗(MEDI4736)(抗PD-L1)联合tremelimumab(抗CTLA-4)与FOLFOX方案治疗转移性结直肠癌患者的安全性、耐受性和免疫活性的Ib/II期试验”的更正:[ESMO Open 3 (2018) e000375]

Fumet, Jean-David; Isambert, Nicolas; Hervieu, Alice; Zanetta, Sylvie; Guion, Jean-Florian; Hennequin, Audrey; Rederstorff, Emilie; Bertaut, Aurélie; Ghiringhelli, Francois

KS01.6.A UCPVAX-GLIO: A PHASE II TRIAL EVALUATING THE IMMUNOGENICITY AND EFFICACY OF AN ANTI-TELOMERASE VACCINE IN PATIENTS WITH NEWLY DIAGNOSED GBM

KS01.6.A UCPVAX-GLIO:一项评估抗端粒酶疫苗在初诊胶质母细胞瘤患者中免疫原性和疗效的II期临床试验

Ware, Kathryn E; Garcia-Blanco, Mariano A; Armstrong, Andrew J; Dehm, Scott M; Carpentier, A F; Verlut, C; Ghiringhelli, F; Bronnimann, C; Ursu, R; Fumet, J; Gherga, E; Lefort, F; Belin, C; Vernerey, D; Mathieu Larroquette, M; Hervieu, A; Laheurte, C; Meurisse, A; Jacquin, M; Malfroy, M; Kroemer, M; Clairet, A; Fagnoni-Legat, C; Lehmann-Che, J; Boullerot, L; Cuzzubbo, s; Adotevi, O

A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer

一项针对转移性多器官癌症患者的I期研究,评估阿特珠单抗、替拉戈鲁单抗和立体定向放射治疗联合疗法的疗效。

Roussot, Nicolas; Fumet, Jean-David; Limagne, Emeric; Thibaudin, Marion; Hervieu, Alice; Hennequin, Audrey; Zanetta, Sylvie; Dalens, Lorraine; Fourrier, Théo; Galland, Loick; Jacob, Pierre; Bertaut, Aurélie; Rederstorff, Emilie; Chevalier, Cédric; Ghirardi, Sarah; Gilbert, Elodie; Khoukaz, Azzat; Martin, Etienne; Nicolet, Constance; Quivrin, Magali; Thibouw, David; Vulquin, Noémie; Truc, Gilles; Rouffiac, Magali; Ghiringhelli, Francois; Mirjolet, Céline

MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells

MEK 抑制可通过在癌细胞中诱导 CXCL10 来克服化学免疫疗法耐药性

Emeric Limagne, Lisa Nuttin, Marion Thibaudin, Elise Jacquin, Romain Aucagne, Marjorie Bon, Solène Revy, Robby Barnestein, Elise Ballot, Caroline Truntzer, Valentin Derangère, Jean-David Fumet, Charlène Latour, Cédric Rébé, Pierre-Simon Bellaye, Coureche-Guillaume Kaderbhaï, Aodrenn Spill, Bertrand